Combined Use of Apatinib Mesylate and Vinorelbine Versus Single Use of Vinorelbine in Triple-negative Breast Cancer
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Triple-negative Breast Cancer
Interventions: DRUG: Vinorelbine + placebo|DRUG: Vinorelbine + Apatinib
Sponsor: Liaoning Tumor Hospital & Institute